Zydus Lifesciences Ltd., a global healthcare leader, has announced a strategic agreement between its wholly owned subsidiary, Zydus Lifesciences Global FZE, and Zhuhai Beihai Biotech Co., Ltd. The partnership grants Zydus exclusive licensing, supply, and commercialization rights for BEIZRAY (Albumin Solubilized Docetaxel Injection) in the US market.
Under the agreement, Beihai Biotech will handle manufacturing and supply, while Zydus will drive commercialization. The deal includes upfront payments, milestone-based incentives, and a share of net profits for Beihai Biotech.
Commenting on the development, President and Chief Executive Officer of Zydus Pharmaceuticals (USA) Inc., Punit Patel stated, “We are pleased to partner with Beihai Biotech for the commercialization of this complex drug product in the US market. The partnership will provide impetus to our strategic focus on high unmet need therapy area, as well as our stated purpose of delivering much-needed medicines to more patients in the country. We are certain that by pooling our resources and knowledge, we will be able to empower more patients and help them lead a better quality of life.”
BEIZRAY is the first clinically validated docetaxel formulation without synthetic excipients like Polysorbate-80 or Sulfobutyl Ether Cyclodextrin. Instead, it uses human-derived albumin, reducing adverse effects and improving patient outcomes. The product received FDA approval on October 23, 2024, and is indicated for Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Gastric Adenocarcinoma, and Head and Neck Cancer.
With an annual market volume of 531,000 units (IQVIA MAT Dec 2024), BEIZRAY offers a promising opportunity in the US oncology market.
